- Home
- JBLU vs HRMY Comparison
JBLU vs HRMY Comparison
Compare JBLU & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- HRMY
- Stock Information
- Founded
- JBLU 1998
- HRMY 2017
- Country
- JBLU United States
- HRMY United States
- Employees
- JBLU N/A
- HRMY N/A
- Industry
- JBLU Air Freight/Delivery Services
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- HRMY Health Care
- Exchange
- JBLU Nasdaq
- HRMY Nasdaq
- Market Cap
- JBLU 2.1B
- HRMY 1.6B
- IPO Year
- JBLU N/A
- HRMY 2020
- Fundamental
- Price
- JBLU $4.79
- HRMY $34.09
- Analyst Decision
- JBLU Sell
- HRMY Strong Buy
- Analyst Count
- JBLU 11
- HRMY 8
- Target Price
- JBLU $4.98
- HRMY $52.88
- AVG Volume (30 Days)
- JBLU 30.5M
- HRMY 729.2K
- Earning Date
- JBLU 04-29-2025
- HRMY 05-06-2025
- Dividend Yield
- JBLU N/A
- HRMY N/A
- EPS Growth
- JBLU N/A
- HRMY 13.13
- EPS
- JBLU N/A
- HRMY 2.62
- Revenue
- JBLU $9,210,000,000.00
- HRMY $744,852,000.00
- Revenue This Year
- JBLU $3.42
- HRMY $20.06
- Revenue Next Year
- JBLU $6.62
- HRMY $18.40
- P/E Ratio
- JBLU N/A
- HRMY $12.76
- Revenue Growth
- JBLU N/A
- HRMY 20.62
- 52 Week Low
- JBLU $3.34
- HRMY $26.47
- 52 Week High
- JBLU $8.31
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- JBLU 57.39
- HRMY 69.87
- Support Level
- JBLU $4.35
- HRMY $29.82
- Resistance Level
- JBLU $4.86
- HRMY $30.61
- Average True Range (ATR)
- JBLU 0.26
- HRMY 1.15
- MACD
- JBLU 0.16
- HRMY 0.71
- Stochastic Oscillator
- JBLU 90.54
- HRMY 98.91
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.